Susan Pandya: U.S. FDA approval of our targeted therapy underscores the efforts of our exceptional clinical research team

Susan Pandya, Vice President of Clinical Development and Global Head of Cancer Metabolism at Servier Pharmaceuticals, recently posted on LinkedIn.

“Today’s U.S. FDA approval of our targeted therapy in IDH1-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS) underscores the efforts of our exceptional clinical research team, Servier Pharmaceuticals, in developing novel therapies for difficult and hard-to-treat cancers.

As the first and only approved targeted therapy for patients diagnosed with R/R MDS within this molecularly defined subset, this new indication reinforces the importance of mutational testing and its impact on improving patient outcomes.

View our full announcement here.”

Source: Susan Pandya/LinkedIn